Goal analysis in patients with limb spasticity treated with incobotulinumtoxinA in the TOWER study.

Fheodoroff, Klemens; Scheschonka, Astrid; Wissel, Jörg

Fheodoroff, Klemens; Scheschonka, Astrid; Wissel, Jörg.

Affiliation

Fheodoroff K; Department of Neurorehabilitation, Gailtal-Klinik Hermagor, Hermagor, Austria.
Scheschonka A; Merz Pharmaceuticals GmbH, Frankfurt am Main, Germany.
Wissel J; Department of Neurology & Neurorehabilitation and Physical Therapy, Vivantes Hospital Spandau, Berlin, Germany.

Disabil Rehabil ; 44(8): 1367-1373, 2022 04.

Article in En | MEDLINE | ID: mdl-32805151

Subject(s)

Botulinum Toxins, Type A; Disabled Persons; Botulinum Toxins, Type A/therapeutic use; Disability Evaluation; Goals; Humans; International Classification of Functioning, Disability and Health; Muscle Spasticity/drug therapy

Key words

Botulinum toxin; Disability and Health; International Classification of Functioning; goal setting; incobotulinumtoxinA; spasticity

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Disabled Persons / Botulinum Toxins, Type A Limits: Humans Language: En Journal: Disabil Rehabil Journal subject: REABILITACAO Year: 2022 Document type: Article Affiliation country: Austria

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google